singularity-biomed.com

What It Is

Singularity Biomed positions itself as a medical technology company focused on “computational rheumatology.” Its core direction is using AI-driven thermal imaging to redefine rheumatoid arthritis assessment. Its goals include early diagnosis of autoimmune diseases, disease monitoring, and research support. According to the website, the company’s technology has completed model development and validation in Spain and is currently undergoing international validation through the AutoPiX project.

Core Capabilities and Typical Use Cases

Its AI capabilities mainly come from machine learning models that analyze joint thermal imaging patterns to identify joint inflammation in patients with rheumatoid arthritis. Compared with traditional physical examination, its selling point is reducing subjectivity and producing quantifiable, reproducible data. The detection workflow emphasizes a “just take a photo” approach, with real-time analysis and reporting completed within seconds. Typical scenarios include bedside point-of-care assessment, remote patient monitoring, and clinical research, especially for drug development and clinical trials that require objective inflammation indicators.

Pricing, Integration, and Privacy

The website does not disclose pricing, procurement models, free trials, or payment methods, nor does it clarify whether there is a software, hardware, or service package available for direct purchase. In terms of integration, it only mentions smartphone-style portable thermal imaging and ease of adoption in clinical environments, without specifying API, SDK, hospital system, or electronic medical record integration capabilities. There is also no public information on data privacy, patient data storage, compliance certifications, or cross-border data processing, so medical institutions will need further due diligence during evaluation.

Pros, Cons, and Limitations

The advantages are that the solution is non-invasive, contactless, radiation-free, and fast, making it theoretically suitable for continuous monitoring and primary care settings. It also has publications in journals such as RMD Open and Diagnostics, as well as exposure at EULAR and PANLAR conferences, giving it a relatively strong scientific evidence base. The limitations are that the website does not provide clear performance metrics, supported device ranges, regulatory approval status, or commercial deployment cases. International validation is still underway, and more evidence is needed on how well the model generalizes across different countries, populations, and devices.

Who It’s For and Access from China

This tool is most relevant for rheumatology and immunology departments, medical imaging and digital therapeutics teams, clinical research organizations, and pharmaceutical clinical trial teams. Access from China, Chinese-language support, and local payment availability are unknown. If used in Chinese medical settings, users will also need to confirm network availability, medical device registration, data compliance, and local service capabilities. Alternative approaches include traditional clinical examination, ultrasound, MRI, and other AI imaging or remote monitoring solutions.